Pulmonary hypertension (PH) is a complex and often misunderstood disease. It is characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, leading to right ventricular failure. This article aims to provide an in-depth understanding of the fundamentals of PH.
PH is a pathophysiological disorder that involves multiple pathways. These include vasoconstriction, vascular remodeling, thrombosis, and inflammation. The endothelial dysfunction leads to an imbalance between vasodilators and vasoconstrictors, contributing to increased pulmonary vascular resistance.
PH often presents insidiously, with nonspecific symptoms such as dyspnea on exertion, fatigue, and syncope. As the disease progresses, right ventricular failure symptoms such as edema and ascites may become apparent. Early diagnosis is crucial to improve patient outcomes.
Diagnosis of PH involves a combination of clinical assessment, echocardiography, and right heart catheterization. An elevated mean pulmonary artery pressure of >20mmHg at rest, as measured by right heart catheterization, is diagnostic of PH. Echocardiography serves as a non-invasive screening tool, while right heart catheterization confirms the diagnosis.
Management of PH involves addressing the underlying cause, symptom control, and slowing disease progression. Therapies include vasodilator drugs, anticoagulants, diuretics, and in severe cases, lung transplantation. A multidisciplinary approach is essential for optimal patient care.
Understanding the fundamentals of PH is vital for early diagnosis and effective management. It is a complex disease that requires a comprehensive diagnostic approach and a multidisciplinary management strategy. By increasing our understanding of PH, we can improve patient outcomes and quality of life.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation